Highest Price Target1
Lowest Price Target1
Consensus Price Target1
Analyst Rating Summary1
| Buy | Overweight | Hold | Underweight | Sell |
|---|---|---|---|---|
| 2 | 1 | 1 | 1 | 0 |
Analyst Firms Making Recommendations1
- Chardan Capital
- JMP Securities
- Morgan Stanley
- Piper Sandler
1calculated from analyst ratings published within the last 3 years
Analyst Ratings for Kaleido Biosciences
date | ticker | Buy Now | Company | Current price | Upside/Downside | Analyst Firm | Analyst & % Accurate | Price Target Change | Rating Change | Previous / Current Rating | Get Alert |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 04/04/2022 | KLDO | Buy Now | Kaleido Biosciences | $0.00 | 1699900% | Chardan Capital | Keay Nakae | $3 → $1.7 | Downgrade | Buy → Neutral | Get Alert |
| 01/31/2022 | KLDO | Buy Now | Kaleido Biosciences | $0.00 | 2999900% | Chardan Capital | Keay Nakae | $11 → $3 | Maintains | Buy | Get Alert |
| 11/12/2021 | KLDO | Buy Now | Kaleido Biosciences | $0.00 | 10999900% | Chardan Capital | Keay Nakae | — | Maintains | Buy | Get Alert |
| 11/03/2021 | KLDO | Buy Now | Kaleido Biosciences | $0.00 | 21999900% | JMP Securities | Gobind Singh | — | Maintains | Market Outperform | Get Alert |
| 10/19/2021 | KLDO | Buy Now | Kaleido Biosciences | $0.00 | 2999900% | Morgan Stanley | Matthew Harrison | — | Downgrade | Equal-Weight → Underweight | Get Alert |
| 03/08/2021 | KLDO | Buy Now | Kaleido Biosciences | $0.00 | 11999900% | Morgan Stanley | Matthew Harrison | — | Maintains | Equal-Weight | Get Alert |
| 02/09/2021 | KLDO | Buy Now | Kaleido Biosciences | $0.00 | 18999900% | Piper Sandler | Edward Tenthoff | — | Initiates | → Overweight | Get Alert |
| 01/19/2021 | KLDO | Buy Now | Kaleido Biosciences | $0.00 | 12999900% | Morgan Stanley | — | — | Maintains | Equal-Weight | Get Alert |
| 12/23/2020 | KLDO | Buy Now | Kaleido Biosciences | $0.00 | 21999900% | JMP Securities | — | — | Initiates | → Outperform | Get Alert |
What is the target price for Kaleido Biosciences (KLDO)?
The latest price target for Kaleido Biosciences (OTCEM: KLDO) was reported by Chardan Capital on April 4, 2022. The analyst firm set a price target for $1.70 expecting KLDO to rise to within 12 months (a possible 1699900.00% upside). 0 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Kaleido Biosciences (KLDO)?
The latest analyst rating for Kaleido Biosciences (OTCEM: KLDO) was provided by Chardan Capital, and Kaleido Biosciences downgraded their neutral rating.
When is the next analyst rating going to be posted or updated for Kaleido Biosciences (KLDO)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Kaleido Biosciences, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Kaleido Biosciences was filed on April 4, 2022 so you should expect the next rating to be made available sometime around April 4, 2023.
Is the Analyst Rating Kaleido Biosciences (KLDO) correct?
While ratings are subjective and will change, the latest Kaleido Biosciences (KLDO) rating was a downgraded with a price target of $3.00 to $1.70. The current price Kaleido Biosciences (KLDO) is trading at is $0.00, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.